

Chemical Science

Accepted Manuscript




This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.




Scheme 2. Synthesis of the 20-C fatty acid. a. (*R*)-**6**, *n*-BuLi, BF₃·Et₂O, THF, -78 °C - rt, 74%. b. Lindlar's cat. H₂, EtOAc, 96%. c. SEMCl, ^tPr₂NEt, CH₂Cl₂, 0 °C - rt, 96%. d. DDQ, pH = 7 buffer/CH₂Cl₂, 0 °C - rt, 97%. e. Dess-Martin periodinane, NaHCO₃, CH₂Cl₂, 0 °C, 90%. f. Bestmann-Ohira reagent, NaOMe, THF, -78 °C, 94%. g. (*S*)-**6**, *n*-BuLi, BF₃·Et₂O, THF, -78 °C - rt, h. Lindlar's cat. H₂, EtOAc. i. DDQ, 4Å MS, CH₂Cl₂, 67%, 3 steps. j. ^tBu₂AlH, CH₂Cl₂, -78 °C 79%. k. Dess-Martin periodinane, pyridine, CH₂Cl₂, 0 °C, 82%. l. **10**, Cp₂ZrHCl, CH₂Cl₂/toluene; Me₂Zn, **12**, -78 - 0 °C, ca. 2:1 d.r. m. Dess-Martin periodinane, NaHCO₃, CH₂Cl₂, 0 °C, 83% 2 steps. n. LiEt₃H, CH₂Cl₂, -78 °C, 97%, >10:1 dr.

The geometry of the five olefins and the identity of the sugar moiety were assigned based on coupling constants, but the other seven oxygenated stereocenters remain ambiguous. Total synthesis provides the only means to procure additional nigricanoside A for detailed biological investigation and complete structural elucidation.⁴ Several groups have reported studies towards this objective, but no structural assignment or total synthesis has been disclosed.⁵ The principle synthetic challenges presented by nigricanoside A include the 17 stereochemical elements, the two unprecedented ether bonds, and the high polarity of the natural product arising from

extensive oxygenation.

Results and Discussion

In designing a synthesis, our primary objective was to design a flexible route that could access all 256 diastereomers (7 isolated stereocenters + D/L galactose). We planned to rely on asymmetric catalysis and chiral auxiliaries to provide multiple stereochemical configurations with equal facility. The initial selection of a target molecule was informed by the structure of trioxilin A3 (**4**), which features a trans diol at C11/C12 and



Scheme 3. Synthesis of the fatty acid portion of nigricanoside A. a. NaH, BrCH₂CO₂H, THF/DMF = 2/1, 0 °C - rt, 91%. b. PivCl, Et₃N, Et₂O, 0 °C; Li-X_c, THF, rt, 91%. c. (*Z*)-1-iodohex-2-ene, NaHMDS (0.9 equiv), THF, -78 °C. 79%, d.r.>20:1, +9% recovered starting material. d. LiBH₄, MeOH, THF, 0 °C, 94%. e. Dess-Martin periodinane, NaHCO₃, CH₂Cl₂, 0 °C, 94%. f. (+)-**17** or (-)-**17**, Cp₂ZrHCl; Me₂Zn; **16**, CH₂Cl₂/toluene, -78 °C - 0 °C. g. DDQ, pH7 buffer/CH₂Cl₂, 0 °C - rt.

reported data for the natural product. The C9/C10 anti diastereomers more closely resembled the natural product than their C9/C10 syn congeners according to ^1H NMR. The chemical shift of the C7 and C9 protons appeared to favor the anti/anti diastereomer **23**, so we elected to advance this stereochemical series in the synthesis, although the anti/syn diastereomer was also similar to the natural product.


The C9 stereocenter was homogenized through chelate-controlled reduction of the corresponding ketone (Scheme 4).^{12, 15} Two high-yielding protecting group manipulations generated a substrate suitable for introduction of the galactose ring (**26**). Specifically, the C8' secondary alcohol was alkylated with the primary triflate **27**.²⁰ This alkylation was only successful with an α -galactose. For example, with β -galactose **28**, elimination of the triflate dominated, affording the exocyclic olefin derived from **28** as the major product. After appending the α -galactose-diacetonide, the PMB groups were exchanged for acetates (**30**) so we could effect global deprotection under mild conditions as the last step of the synthesis. Next, the anomeric position of the galactose was activated through a sequence that involved removal of the acetonides and per-acylation of the galactose alcohols. The anomeric acetate was hydrolyzed, and addition of trichloroacetonitrile formed the trichloroacetimidate **31**.²¹ Reaction with (*S*)-solketal (**33**) in the presence of TMSOTf provided the full skeleton of nigriganoside A (**32**). In this glycosylation, 5Å MS were uniquely effective. Remarkably, 4Å MS inhibited formation of the desired product, a difference we attribute to the decreased basicity of 5Å MS compared to 4Å MS.²²

On the cusp of completion, we were eager to remove the acetonide and acetate groups, which was accomplished with *p*-toluene sulfonic acid and NaOMe, respectively. We were concerned, however, by the ominous observation that the final diester (**32**) could not be dissolved in the DMSO- d_6 /C $_6$ D $_6$ (2:25) mixture used in the original isolation. Ultimately, we were able to coerce the synthetic compound into solution by concentrating it from a solution in d_4 -methanol to form a thin film in a vial (concentration from water/CH $_3$ CN provided a solid). The ^1H NMR of our synthetic material did not match that reported for the natural product. Moreover, the synthetic compound was inactive against HCT-116 and MCF-7 cells, whereas nigriganoside A dimethyl ester was reported to show low nM toxicity against these cell lines.

While we were disappointed to have prepared an isomer of the natural product, our reliance on asymmetric catalysis and chiral auxiliaries to dictate stereochemistry in our synthesis provided substantial flexibility. By design, we could prepare nearly any other diastereomer using the same overall strategy. In this context, the most obvious differences between the ^1H NMR spectra for diester **32** and nigriganoside A dimethyl ester were associated with the C7-C8 trans olefin. This observation suggested that the natural product might feature a C6/C9 syn relationship. To test this hypothesis, the fatty acid fragment **21** was converted to the triol **34** using substantially the same chemistry as described above, with the addition of a Mitsunobu reaction to invert C8' (Scheme 5, see supporting information).²³ This latter inversion was based on the conjecture, which ultimately proved correct, that the two fatty acid fragments likely possessed the same relative stereochemistry within the 1, 2, 5-triol moieties. Finally, we proceeded to install the glycerol subunit analogously to the path developed for **32**. The 1D (^1H , ^{13}C) and 2D NMR data (COSY, HSQC, HMBC) of the dimethyl ester (**2**) exactly matched that reported for nigriganoside dimethyl ester. Optical rotation values indicated that we had prepared the natural enantiomer ($[\alpha]^{20} = -22$, $c =$

$0.1 \text{ CH}_2\text{Cl}_2$; lit $[\alpha]^{25} = -42$, $c = 0.24 \text{ CH}_2\text{Cl}_2$). By contrast, the C2''' epimer of **2** was clearly distinct from the natural product. In particular, the five resolvable C-H resonances of the glycerol subunit were shifted by 0.03-0.16 ppm relative to reported data for nigriganoside dimethyl ester.

We were surprised to find that neither **2** nor its C2''' epimer showed any toxicity towards HCT116 or MCF7 cells up to 10 μM . The isolation group additionally observed no toxicity from our synthetic material nor did they detect any mitotic arrest arising from treatment with synthetic **2**. None of the original sample is available for side-by-side comparison in biological assays, but it appears that nigriganoside A is not cytotoxic.



Scheme 5. Synthesis of nigriganoside A dimethyl ester (**2**). See Supporting Information for synthetic details.

Conclusions

The absence of biological activity for synthetic **2** presents an enigma that remains to be resolved. No ambiguity exists regarding the structure; the natural and synthetic material yield matching spectra and optical rotations. Moreover, all of the diastereomers we have prepared show clearly distinct ^1H NMR spectra, minimizing the likelihood that we prepared a diastereomer of the natural product that coincidentally yields identical spectra.²⁴ To highlight the identity of our synthetic material with the naturally derived material, Figure 1 shows an overlay of the olefin region of synthetic and natural **2**, which illustrates that not only do the chemical shifts and coupling constants match, the complex patterns of the peaks are identical. Likewise, the isolation group documented several biological activities associated with nigriganoside A dimethyl ester including cytotoxicity, mitotic arrest and tubulin polymerization. These activities were observed in both crude fractions and purified materials. The rigor of their studies argues against an artifactual result. The naturally occurring

samples show approximately 90% purity. Minor resonances in the published ^1H NMR spectrum could represent an unidentified source for the observed biological activity. Intriguingly, the only clear peaks for the minor component resemble the C7-C8 olefin resonances, suggesting a structural relationship to nigricanoside A. Finally, diester **2** was isolated along with a close congener, nigricanoside B dimethyl ester (**3**, Scheme 1 above). The Anderson and Roberge groups found that this secondary metabolite was more than 100-fold less active than nigricanoside A, which would be a surprisingly large drop in activity for a small structural change. A more likely interpretation in our view is that an unidentified natural product co-eluted with nigricanoside A dimethyl ester. Remarkably, the high potency reported for the natural product (~3 nM) would require sub-nanomolar toxicity for any minor contaminant. This possibility should provide incentive for future efforts to identify the unknown highly active antimetabolite.




Figure 1. Olefin region of the ^1H NMR of synthetic and natural nigricanoside A dimethyl ester.

Acknowledgements

We thank Dr. Deepak Nijhawan and Maria Goralski (UT Southwestern) and Dr. Michel Roberge (Univ. of British Columbia) for biological testing, and Raymond Andersen for helpful discussions. Funding provided by CPRIT (100976), NIH (R01GM102403) and the Welch Foundation (I-1612 to J.M.R.; I-1689 to J.B.M.). J.B.M. is the Chilton/Bell Scholar in Biochemistry.

Notes and references

^a Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX USA 75390-9038

Electronic Supplementary Information (ESI) available: Complete experimental details and characterization data. See DOI: 10.1039/b000000x/

- 1 D. E. Williams, C. M. Sturgeon, M. Roberge and R. J. Andersen, *J. Am. Chem. Soc.*, 2007, **129**, 5822-5823.
- 2 P. Dormann and C. Benning, *Trend Plant Sci.*, 2002, **7**, 112-118.
- 3 Raymond Andersen, personal communication.
- 4 Reviews on structure assignment by total synthesis: (a) K. C. Nicolaou, S. A. Snyder, *Angew. Chem. Int. Ed.* 2005, **44**, 1012. (b) M. E. Maier, *Nat Prod Rep* 2009, **26**, 1105. (c) T. L. Suyama, W. H. Gerwick, K. L. McPhail, *Bioorg. Med. Chem.* 2011, **19**, 6675.
- 5 Synthetic studies towards nigricanoside A: (a) M. Tortosa, *Angew. Chem. Int. Ed.* 2011, **50**, 3950; (b) Y. Kurashina and S. Kuwahara, *Biosci. Biotechnol. Biochem.* 2012, **76**, 605-607; (c) N. Kinashi, K. Fujiwara, T. Tsunoda, R. Katoono, H. Kawai and T. Suzuki, *Tetrahedron Lett.*, 2013, **54**, 4564-4567; (d) G. A. Abeykoon, S. Chatterjee, J. S. Chen, Abstracts of Papers, 246th National Meeting of the American Chemical Society, Indianapolis, IN, Sep 8-12, 2013; American Chemical Society: Washington DC, 2013; ORGN-36; (e) S. R. De, G. Kumar, J. L. Jat, S. Birudaraju, B. Lu, R. Manne, N. Puli, A. M. Adebesein, J. R. Falck, *J. Org. Chem.* 2014, **79**, 10323..
- 6 (a) C. R. Pace-Asciak, *J. Biol. Chem.*, 1984, **259**, 8332-8337. (b) C. R. Pace-Asciak and W. S. Lee, *J. Biol. Chem.*, 1989, **264**, 9310-9313.
- 7 A. P. D. M. Espindola, R. Crouch, J. R. DeBergh, J. M. Ready and J. B. MacMillan, *J. Am. Chem. Soc.*, 2009, **131**, 15994-15995.
- 8 M. Yamaguchi, I. Hirao, *Tetrahedron Lett.* 1983, **24**, 391.
- 9 S. Mueller, B. Liepold, G. J. Roth and H. J. Bestmann, *Synlett*, 1996, 521-522.
- 10 C. Zanato, L. Pignataro, A. Ambrosi, Z. Hao, C. Trigili, J. F. Díaz, I. Barasoain and C. Gennari, *Eur. J. Org. Chem.*, 2011, **2011**, 2643-2661.
- 11 The absolute stereochemistry of the C8', C11' and C9 alcohols were confirmed through analysis of the Mosher's ester. See Supporting information. M. J. Rieser, Y. H. Hui, J. K. Rupprecht, J. F. Kozlowski, K. V. Wood, J. L. McLaughlin, P. R. Hanson, Z. Zhuang and T. R. Hoye, *J. Am. Chem. Soc.*, 1992, **114**, 10203-10213.
- 12 P. Wipf and W. Xu, *Tetrahedron Lett.*, 1994, **35**, 5197-5200.
- 13 (a) P. Wipf and S. Ribe, *J. Org. Chem.*, 1998, **63**, 6454-6455. (b) A. E. Lurain, P. J. Carroll and P. J. Walsh, *J. Org. Chem.*, 2005, **70**, 1262-1268.
- 14 (a) A.-M. Faucher, C. Brochu, S. R. Landry, I. Duchesne, S. Hantos, A. Roy, A. Myles, C. Legault, *Tetrahedron Lett.* 1998, **39**, 8425. (b) S.-M. Paek, S.-Y. Seo, S.-H. Kim, J.-W. Jung, Y.-S. Lee, J.-K. Jung, Y.-G. Suh, *Org. Lett.* 2005, **7**, 3159.
- 15 Syntheses of trioxilin: (a) S. Lumin, P. Yadagiri and J. R. Falck, *Tetrahedron Lett.*, 1988, **29**, 4237-4240. (b) S. Lumin, J. R. Falck, J. Capdevila and A. Karara, *Tetrahedron Lett.*, 1992, **33**, 2091-2094. (c) J. S. Yadav and P. Vadapalli, *Tetrahedron Lett.*, 1994, **35**, 641-644. (d) see also: E. J. Corey and W.-g. Su, *Tetrahedron Lett.*, 1984, **25**, 5119-5122.

-
- 16 D. A. Evans, M. D. Ennis and D. J. Mathre, *J. Am. Chem. Soc.*, 1982, **104**, 1737-1739.
- 17 M. T. Crimmins, K. A. Emmitte and J. D. Katz, *Org. Lett.*, 2000, **2**, 2165-2167.
- 18 K. Matsumura, S. Hashiguchi, T. Ikariya and R. Noyori, *J. Am. Chem. Soc.*, 1997, **119**, 8738-8739.
- 19 Alkyne **17** and *ent*-**17** were synthesized in 5 steps and 99% ee from adipic anhydride: 1. Opening with bis-TMS acetylene; 2. *tert*-Butyl ester formation; 3. Noyori reduction; 4. PMB protection; 5. desilylation. See supporting information for details.
- 20 W. Xie, G. Tanabe, J. Akaki, T. Morikawa, K. Ninomiya, T. Minematsu, M. Yoshikawa, X. Wu and O. Muraoka, *Bioorg. Med. Chem.*, 2011, **19**, 2015-2022.
- 21 R. R. Schmidt and J. Michel, *Angew. Chem. Int. Ed.*, 1980, **19**, 731-732.
- 22 (a) M. Mizuno, K. Kobayashi, H. Nakajima, M. Koya and T. Inazu, *Synthetic Commun.*, 2002, **32**, 1665-1670; (b) The pH of a mixture of molecular sieves and water after 5h was 10 (3Å MS), 8 (4Å MS) and 7 (5Å MS).
- 23 O. Mitsunobu, *Synthesis*, 1981, **1981**, 1-28.
- 24 NMR data for two additional diastereomers is presented in the supporting information.